OBJECTIVETo evaluate the validity of Chinese drugs for reinforcing Shen and regulating Chong channel (RSRCC) on patients with polycystic ovarian syndrome (PCOS) undergoing in vitro fertilization and embryo transplantation (IVF-ET).

METHODSSixty-four patients with PCOS undergoing IVF-ET were randomly assigned to two groups, the treated group (36 cases) and the control group (28 cases), to the former, Chinese recipe for RSRCC was given additionally.

RESULTSOn the human chorionic gonadotrophin (HCG) injecting day, the percentage of three-line sign of endometrium (type A) in the treated group was 75.0% (27/36), which was higher than that in the control group (42.9%, 12/28), showing significant difference between the two groups (P < 0.01). The rates of mature oocytes, fertilization, high-qualified embryo rate, clinical pregnancy rate and incidence rate of ovary hyper-stimulating syndrome (OHSS) in the treated group were (76.8 +/- 8.2)%, (73.5 +/- 8.9)%, (89.4 +/- 14.4)%, 36.11% (13/36) and 5.56% (2/36), respectively; whereas those in the control group (64.4 +/- 8.7)%, (68.2 +/- 10.0)%, (79.5 +/- 15.2)%, 21.43% (6/28) and 10.71% (3/28); the dosage of gonadotrophin administered in the treated group was 33.8 +/- 12.5 ampoules, and in the control group 47.6 +/- 18.2 amp oules, statistical significance was shown between groups in comparing all the above-mentioned parameters (P <0.05, P <0.01). However, the number of oocytes obtained in the two groups was insignificantly different (P > 0.05).

CONCLUSIONCombined use of Chinese drugs for RSRCC in IVF-ET can reduce the dosage of gonadotrophin administered and raise the clinical pregnant rate.